CA Intermediate · Advanced Accounting · AS 26 Intangible Assets
Sundaram Software Ltd. incurred Rs 18,00,000 on a project to develop a new billing application. Research phase cost Rs 6,00,000. Development phase cost Rs 12,00,000, of which Rs 4,00,000 was spent before the company could demonstrate technical feasibility and the remaining Rs 8,00,000 after all AS 26 recognition criteria were met. What amount is recognised as an intangible asset?
Rs 8,00,000 is capitalised. Research cost is always an expense, and development cost is capitalised only from the point when all recognition criteria are met. The Rs 4,00,000 spent before feasibility was shown is expensed and cannot be added to the asset later.
- ARs 18,00,000
- BRs 12,00,000
- CRs 8,00,000Correct
- DRs 14,00,000
Explanation
Research expenditure (Rs 6,00,000) is always expensed. Development expenditure is capitalised only from the date all criteria are met, so only Rs 8,00,000 is capitalised. The Rs 4,00,000 incurred earlier is expensed and cannot be reinstated later. Rs 12,00,000 wrongly capitalises all development cost.
Did you get it right without looking?
One question tells you little. A timed set on AS 26 Intangible Assets shows your real accuracy, how long you take and where you lose marks.
More AS 26 Intangible Assets questions
- Bharat Foods Ltd. purchased a brand licence on 1 July 2024 for Rs 24,00,000 with useful life of 6 years and nil residual value, amortised st…
- Narmada Infotech Ltd acquired a patent on 1 April 2022 for ₹48 lakh and amortised it on the straight-line method over an estimated useful li…
- Kaveri Pharma Ltd is developing a new formulation. Research costs of ₹14 lakh were incurred from April to June. Development costs of ₹9 lakh…
- Sundaram Ltd purchased a licence on 1 April 2025 for Rs 24 lakh, amortised over 6 years straight-line with nil residual value. On 31 March 2…
- Anand Ltd. acquired a patent on 1 April 2023 for Rs 20,00,000 with useful life of 10 years, amortised straight-line, nil residual. On 31 Mar…
- Kaveri Pharma Ltd incurred Rs 12 lakh on a research phase of a new drug formulation and, after technical feasibility was demonstrated and al…